DB200

	Lead Identification	Candidate Selection Proof of Principle	Pre-Clinical Development	Phase 1	Phase 2a
Development Phase

Product/Technology Name: DB200

Condition/Disease Targeted: Psoriasis

Purpose: DB200 is a small molecule regulator of fatty acid homeostasis.  The molecule in a topical formulation is being developed as a therapy for the treatment of psoriasis. 

Product Development: DB200 is in pre-clinical development with an IND submission targeted for 2009.

Viability: The mechanism of action is complementary to existing therapies and, in combination with steroids, delivers superior efficacy to steroids alone.